Minimal Residual Disease (MRD) ratio before and after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma

被引：0
|
作者：
Boncompagni, Riccardo [1 ]
Staderini, Michela [2 ]
Nozzoli, Chiara [1 ]
Antonioli, Elisabetta [2 ]
Caporale, Roberto [3 ]
Peruzzi, Benedetta [3 ]
Cutini, Ilaria [1 ]
Gozzini, Antonella [1 ]
Serena, Mariotti [1 ]
Guidi, Stefano [1 ]
Jance, Blerina [3 ]
Accogli, Barbara [2 ]
Francesco, Annunziato [3 ]
Bosi, Alberto [2 ]
Saccardi, Riccardo [1 ]
机构：
[1] AOU Careggi, Cell Therapy & Transfus Med Unit, Florence, Italy
[2] AOU Careggi, Hematol Unit, Florence, Italy
[3] AOU Careggi, Diagnost Ctr Cytometry & Immunotherapy, Florence, Italy
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
autologous stem cell transplant; Minimal residual disease; Progression-free survival;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FP-203
引用
收藏
页码：E172 / E172
页数：1
相关论文
共 50 条
  • [41] Pre-Transplant M Protein Level Predicts Minimal Residual Disease Status after Autologous Stem Cell Transplantation in Multiple Myeloma
    Meyer, Zachary S.
    Manaa, Mohamed
    Han, Yan
    Czader, Magdalena
    Suvannasankha, Attaya
    Abonour, Rafat
    Farag, Sherif S.
    Stanley, Melissa
    Abu Zaid, Mohammad Issam
    BLOOD, 2021, 138
  • [42] The Value of Minimal Residual Disease as a Progression-Free Survival Predictor After Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients
    Solovev, Maxim
    Mendeleeva, Larisa
    Firsova, Maiia
    Julhakyan, Hunan
    Galtseva, Irina
    Davydova, Julia
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S324 - S324
  • [43] Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments
    Kalff, Anna
    Kennedy, Nola
    Walker, Patricia A.
    Khong, Tiffany T.
    Schwarer, Anthony
    Roberts, Andrew W.
    Campbell, Philip
    Filshie, Robin
    Smiley, Angela
    Gorniak, Malgorzata
    Black, Marion
    Jenkins, Nicole
    Raines, Geoffrey
    Spencer, Andrew
    BLOOD, 2014, 124 (21)
  • [44] The clinical significance of the monitoring minimal residual disease for maintanence therapy after autologous stem cells transplantation in patients with multiple myeloma
    Shamansky, S.
    Fedotova, I.
    Novoseltceva, L.
    Melkova, C.
    Pisarevskaya, O.
    Rukavitcin, O.
    BONE MARROW TRANSPLANTATION, 2015, 50 : 5597 - 5598
  • [45] Effect of Immunomodulatory Drugs (IMiDs) on Immune Effectors after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma
    Foureau, David M.
    Bhutani, Manisha
    Zhang, Qing
    Robinson, Myra M.
    Wynn, Adina
    Steuerwald, Nury M.
    Druhan, Lawrence J.
    Guo, Fei
    Rigby, Katherine
    Turner, Mitchell
    Friend, Reed
    Atrash, Shebli
    Sprouse, Chelsea
    Ndiaye, Ami
    Symanowski, James T.
    Avalos, Belinda Rene
    Copelan, Edward A.
    Voorhees, Peter M.
    Usmani, Saad Z.
    BLOOD, 2017, 130
  • [46] Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: A retrospective study
    Liu, Hong
    Yuan, Constance
    Heinerich, Jeremy
    Braylan, Raul
    Chang, Myron
    Wingard, John
    Moreb, Jan
    LEUKEMIA & LYMPHOMA, 2008, 49 (02) : 306 - 314
  • [47] Glivec treatment for Ph-positive (Ph+) leukemias who relapsed before or after allogeneic stem cell transplantation (ASCT) with intensive monitoring of minimal residual disease (MRD)
    Yamada, M
    Miyamura, K
    Sasaki, O
    Kamcoka, J
    Meguro, K
    Sasaki, T
    EXPERIMENTAL HEMATOLOGY, 2002, 30 (06) : 135 - 135
  • [48] Lenalidomide after autologous stem cell transplantation in multiple myeloma
    Sanchez, A.
    Notario, C.
    Rios, P.
    Brena, J.
    Oliva, A.
    Afonso, V.
    Rios, M.
    Marreno, C.
    Hermandez, N.
    Cabello, A.
    Jover, S.
    Leon, A.
    Trujillo, M.
    Mesa, C.
    Perez, G.
    Herrera, M.
    Garcia-Talavera, J.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S330 - S330
  • [49] KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation
    Cowan, Andrew J.
    Green, Damian J.
    Karami, Mehdi
    Becker, Pamela S.
    Tuazon, Sherilyn
    Coffey, David G.
    Hyun, Teresa S.
    Libby, Edward N.
    Gopal, Ajay K.
    Holmberg, Leona A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (09): : 602 - 609
  • [50] Monitoring of minimal residual disease after autologous stem cell transplantation in adult AML patients
    Maurillo, L
    Tamburini, A
    Buccisano, F
    Del Principe, MI
    Venditti, A
    Del Poeta, G
    De Fabritiis, P
    Amadori, S
    BONE MARROW TRANSPLANTATION, 2003, 31 : S122 - S123
12345